JAHA:前向左室射血分数预测二尖瓣反流患者的预后要更优

2017-10-28 MedSci MedSci原创

在无症状的二尖瓣反流(MR)病人中,手术时机的选择仍存在争议。作者提出一个假设:前向左室射血分数(LVEF)在预测MR患者预后方面要优于总体LVEF。本研究目的旨在通过心超评估MR和左室功能参数与MR患者预后的关系。本次回顾性分析研究纳入了278名中度及以上尚无手术指征的MR患者,并对其心超和临床信息进行分析评估。主要终点事件为二尖瓣手术或者死亡。经过平均5.4±3.2年时间的随访,共出现96次(

在无症状的二尖瓣反流(MR)病人中,手术时机的选择仍存在争议。作者提出一个假设:前向左室射血分数(LVEF)在预测MR患者预后方面要优于总体LVEF。本研究目的旨在通过心超评估MR和左室功能参数与MR患者预后的关系。

本次回顾性分析研究纳入了278名中度及以上尚无手术指征的MR患者,并对其心超和临床信息进行分析评估。主要终点事件为二尖瓣手术或者死亡。经过平均5.4±3.2年时间的随访,共出现96次(35%)二尖瓣手术和66次(24%)死亡。总体LVEF和纵向应变力与主要终点事件的发生不呈相关性,而前向LVEF((P<0.0001)和左室收缩末期直径(P=0.0003)与主要终点事件的发生呈相关性。校正年龄、性别、MR的严重程度、冠状动脉疾病和心房颤动等因素后,前向LVEF与主要终点事件的发生仍保持相关性(HR:1.09, [95% Cl]: 1.02-1.17; P=0.01),而左室收缩末期直径不呈相关性(P=0.48)。

研究结果显示,前向左室射血分数在预测MR患者预后方面要优于总体LVEF和左室收缩末期直径。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700463, encodeId=fc1a1e004630c, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Aug 25 09:20:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267579, encodeId=e0bb126e57928, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463174, encodeId=a1c414631e449, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571606, encodeId=576815e1606d8, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256706, encodeId=2b96256e060e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Sat Oct 28 16:46:16 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1700463, encodeId=fc1a1e004630c, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Aug 25 09:20:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267579, encodeId=e0bb126e57928, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463174, encodeId=a1c414631e449, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571606, encodeId=576815e1606d8, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256706, encodeId=2b96256e060e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Sat Oct 28 16:46:16 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-30 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=1700463, encodeId=fc1a1e004630c, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Aug 25 09:20:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267579, encodeId=e0bb126e57928, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463174, encodeId=a1c414631e449, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571606, encodeId=576815e1606d8, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256706, encodeId=2b96256e060e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Sat Oct 28 16:46:16 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-30 wwzzly
  4. [GetPortalCommentsPageByObjectIdResponse(id=1700463, encodeId=fc1a1e004630c, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Aug 25 09:20:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267579, encodeId=e0bb126e57928, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463174, encodeId=a1c414631e449, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571606, encodeId=576815e1606d8, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256706, encodeId=2b96256e060e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Sat Oct 28 16:46:16 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-30 feifers
  5. [GetPortalCommentsPageByObjectIdResponse(id=1700463, encodeId=fc1a1e004630c, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Aug 25 09:20:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267579, encodeId=e0bb126e57928, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463174, encodeId=a1c414631e449, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571606, encodeId=576815e1606d8, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Mon Oct 30 03:20:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256706, encodeId=2b96256e060e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Sat Oct 28 16:46:16 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-28 微分

    谢谢分享.学习了

    0

相关资讯

PDE5抑制剂原治心血管?这些新药原来都是“美丽的意外”

新药的研发之路漫长修远,充满了未知和意外。有时一些偶然的意外甚至失败,却能带来意想不到的惊喜。比如人们所熟知的青霉素,是霉菌孢子意外掉入弗莱明的细菌培养皿中被发现的;很多药物原本是为了治疗某个疾病而研制,却被发现对其他疾病有疗效。伟哥:心血管疾病药物意外成为“壮阳药”提起“伟哥”,很多人都知道是“壮阳药”,能够有效治疗男子阴茎勃起功能障碍。但不为人知的是,“伟哥”名叫“西地那非”,最早是作为治疗心

Diabetes Obes Metab:超敏C反应蛋白和LDL-C与2型糖尿病患者的心血管结局!

由此可见,hsCRP水平与2型糖尿病和新近急性冠状动脉综合征患者再发心血管事件相关,这种关联似乎独立于LDL-C的达标水平。

Arterioscl Throm Vas:心血管疾病患者的新福音

科学家们的突破性发现可能改变我们治疗胆固醇的方式。研究人员发现了新的证据,证明了40年的观念,即我们如何快速地从身体中消除它。

做对了这几件事,血压从170降到110!

郑渊洁——著名的儿童文学作家。不仅是因为他笔下的“《皮皮鲁&鲁西西》、《舒克和贝塔历险记》 ”等,还因为他在得了高血压后,天天坚持素食、六成饱和运动等自己的方法,让血压从170降到110,一下子称为降压名人。

SCI REP:高血压和糖尿病对老年人心血管和全因死亡率的影响!

研究人员发现男性比女性受试者HTN/DM状态与卒中发病率和全因死亡率之间存在更强的关联(相互作用的P <0.05)。相比于HTN+/DM−的受试者,HTN−/DM+受试者的全因死亡率增加62%,然而,对于冠心病、脑卒中发病率和CVD死亡率它们没有很大的差异。

JAHA:外用NSAIDs vs 口服NSAIDs——心血管疾病发生风险的比较性研究

人体对外用的非甾体类抗炎药(NSAIDs)的吸收要低于口服类NSAIDs。近日,在国际心血管权威杂志JAHA上发表了一篇旨在评估风湿性关节炎患者接受非选择性外用NSAIDs和口服NSAIDs治疗心血管疾病发生风险的临床研究。本次回顾性分析研究纳入了最近开始接受非选择性外用NSAIDs或口服NSAIDs治疗的风湿性关节炎患者,首次接受两种非甾体抗炎药治疗的日期被定义为索引日期,NSAID治疗的持续时